Mica Duran

Vedolizumab® 

Prev Next
Previous

Male with Organs and Inflammatory Bowel

medical illustration of Monoclonal antibody drug Vedolizumab®. An anti-integrin therapy with a selective mechanism of action, for use in primary types of inflammatory bowel disease - ulcerative colitis and Crohn's disease.
Next medical illustration of Part of a series; E-learning and booth graphics for therapeutic monoclonal antibody Daclizumab (Zenapax®) — Showing blockage of IL-2 receptor target. Drug's mechanism of action graphics at cellular level for pharmaceutical project. Keywords: molecular biology, cellular biology, histology, pharmacology, virology, disease management; multiple sclerosis

Daclizumab— Blockage of dendritic cell receptor

Monoclonal antibody drug Vedolizumab®. An anti-integrin therapy with a selective mechanism of action, for use in primary types of inflammatory bowel disease - ulcerative colitis and Crohn's disease.

Keywords: Color, Advertising / Marketing, Editorial, Education, Web, Cell biology / Histology, Disease Management, Molecular Biology, Pharmacology, Virology

© Mica Duran